שולי רווח תפעולי Syros Pharmaceuticals, Inc. (SYRS)

Syros Pharmaceuticals (SYRS) innovative approach to reprogramming cancer cells correlates with the fact that operational efficiency dynamics on GURU.Markets contain the value 0.00. The company is currently restructuring its debt and seeking buyers for its patents following unsuccessful tests. However, future share price growth depends on the results of the Phase 3 clinical trials for tamibarotene and FDA approval.
SYRS (Syros Pharmaceuticals): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Outsourcing production to CMO facilities minimizes capital expenditures for Syros Pharmaceuticals (SYRS), directly impacting the efficiency of cost management. This operating profit margin is calculated as the ratio of operating income to revenue, allowing investors to assess the commercial profitability of the business excluding debt obligations and taxes, thereby identifying consolidation phases prior to potential market downturns.